CardiacWire

NOVEMBER 12, 2023

The US obesity management arena gained a major new competitor last week with the FDA approval of Eli Lilly’s Zepbound, giving obese and overweight patients in the US a second (on-label) option beyond Novo Nordisk’s Wegovy. Zepbound is Lilly’s new obesity-targeted brand for tirzepatide, which has been available to US diabetic patients under its Mounjaro brand since May 2022 Although often referred to as a GLP-1, tirzepatide uniquely activates both GIP (affects adipose tissue regulation and storag

Obesity 52

Obesity Diabetes Blood Pressure Cholesterol 52

American Heart News - Heart News

NOVEMBER 12, 2023

Research Highlights: Bleeding was reduced by more than 60% among people taking the anti-clotting agent abelacimab, demonstrating its safety for people at risk of stroke from atrial fibrillation. Abelacimab was compared with another standard-of-care.

Atrial Fibrillation 52

Atrial Fibrillation Research Stroke Strokes 52

Dr. S. Venkatesan MD

NOVEMBER 12, 2023

It is still a huge mystery, why the father of medicine stressed more about “not doing bad” than “doing good” What made him to hold on to, such pessimistic thoughts , 2500 years ago. I am unable to think how he would react to this “tampered version” if he is alive ! My gut feeling is, he will find it hard to object.

52

52

American Heart News - Heart News

NOVEMBER 12, 2023

Research Highlights: In a large study of adults with implanted heart devices that detected short, symptomless bouts of irregular heart rhythm, known as subclinical atrial fibrillation, those who took the anti-clotting medication apixaban were 37% less.

Heart Rhythm 52

Heart Rhythm Atrial Fibrillation Stroke Strokes 52

Heart Sisters

NOVEMBER 12, 2023

Study: 3/4 of physicians first delivered bad news to a patient while still a med student, yet only 10% were supervised by a senior physician.

Education 52

Education 52

American Heart News - Heart News

NOVEMBER 12, 2023

Research Highlights: While currently available PCSK9 inhibitor medications to lower cholesterol must be administered every few weeks by injection, a new, investigational PCSK9 inhibitor called recaticimab safely lowered bad cholesterol more than 50%.

Cholesterol 52

Cholesterol Research 52

JAMA Cardiology

NOVEMBER 12, 2023

The concept that the totality of environmental exposures, from the prenatal period and throughout life, affect health is termed the exposome, which was coined in 2005 by Wild as a complement to genomics to capture the breadth of environmental exposures on a person’s health risk. Wild argued that there was a critical need to address environmental factors, starting with developing reliable exposure assessment tools comparable in rigor with methods used in genomics.

Cardiovascular Disease 40

Cardiovascular Disease Risk Factors 40

JAMA Cardiology

NOVEMBER 12, 2023

This cross-sectional study evaluates associations between environmental burden and cardiovascular risk factors and diseases at the neighborhood level and by levels of social vulnerability.

Risk Factors 40

Risk Factors 40

Clinical Trial Results

NOVEMBER 12, 2023

Disclosures 100 19370 0 19370 0 0 207k 0 --:--:-- --:--:-- --:--:-- 207k : TBD

40

40

JAMA Cardiology

NOVEMBER 12, 2023

This post hoc analysis of the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) randomized clinical trial investigates if torsemide improves mortality and hospitalization outcomes at 12 months compared with furosemide in either de novo heart failure or worsening chronic heart failure.

Heart Failure 40

Heart Failure Hospital Outcomes 40

ECG Weekly Workout

NOVEMBER 12, 2023

This content is for members only

Tachycardia 40

Tachycardia 40

Circulation

NOVEMBER 12, 2023

Circulation, Ahead of Print.

Sudden Cardiac Death 40

Sudden Cardiac Death Circulation 40

Clinical Trial Results

NOVEMBER 12, 2023

Disclosures: TBD

Cholesterol 40

Cholesterol 40

Circulation

NOVEMBER 12, 2023

Circulation, Ahead of Print.

Heart Failure 40

Heart Failure Circulation 40

Clinical Trial Results

NOVEMBER 12, 2023

Disclosures: TBD

40

40

Circulation

NOVEMBER 12, 2023

Circulation, Ahead of Print. Background:Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies.Methods:This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Pa

Sudden Cardiac Death 40

Sudden Cardiac Death COVID-19 Cardiomyopathy Research 40

American Heart News - Heart News

NOVEMBER 12, 2023

Research Highlights: In this first trial in people, a single dose of a new therapeutic called lepodisiran reduced the harmful risk factor lipoprotein(a), or Lp(a), by up to 94%, with reductions lasting nearly a year. Lepodisiran is a small interfering.

Risk Factors 52

Risk Factors Research 52

Circulation

NOVEMBER 12, 2023

Circulation, Ahead of Print.

Pulmonary 40

Pulmonary Hypertension Circulation 40

American Heart News - Heart News

NOVEMBER 12, 2023

Research Highlights: In an interim report from the first study in people, a single infusion of a gene-editing therapy significantly reduced bad cholesterol (LDL-C) in people at high risk of early heart attack due to an inherited form of high.

Cholesterol 52

Cholesterol Heart Attack Heart attacks Research 52